Cardiac fibrosis - A short review of causes and therapeutic strategies

Svenja Hinderer; Katja Schenke-Layland

doi:10.1016/j.addr.2019.05.011

Cardiac fibrosis - A short review of causes and therapeutic strategies

Adv Drug Deliv Rev. 2019 Jun:146:77-82. doi: 10.1016/j.addr.2019.05.011. Epub 2019 May 31.

Authors

Svenja Hinderer¹, Katja Schenke-Layland²

Affiliations

¹ Department of Women's Health, Research Institute for Women's Health, Eberhard Karls University, Silcherstrasse 7/1, 72076 Tübingen, Germany; The Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Markwiesenstr. 55, 72770 Reutlingen, Germany.
² Department of Women's Health, Research Institute for Women's Health, Eberhard Karls University, Silcherstrasse 7/1, 72076 Tübingen, Germany; The Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Markwiesenstr. 55, 72770 Reutlingen, Germany; Department of Medicine/Cardiology, Cardiovascular Research Laboratories, David Geffen School of Medicine at UCLA, 675 Charles E. Young Drive South, MRL, 3645 Los Angeles, CA, USA. Electronic address: katja.schenke-layland@med.uni-tuebingen.de.

PMID: 31158407
DOI: 10.1016/j.addr.2019.05.011

Abstract

Fibrotic diseases cause annually more than 800,000 deaths worldwide, whereof the majority accounts for lung and cardiac fibrosis. A pathological remodeling of the extracellular matrix either due to ageing or as a result of an injury or disease leads to fibrotic scars. In the heart, these scars cause several cardiac dysfunctions either by reducing the ejection fraction due to a stiffened myocardial matrix, or by impairing electric conductance, or they can even lead to death. Today it is known that there are several different types of cardiac scars depending on the underlying cause of fibrosis. In this review, we present an overview of what is known about cardiac fibrosis including the role of cardiac cells and extracellular matrix in this disease. We will further summarize current diagnostic tools and highlight pre-clinical or clinical therapeutic strategies to address cardiac fibrosis.

Keywords: Cardiac ECM; Collagen; Fibrosis; Myocardium.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adrenergic beta-Antagonists / pharmacology*
Animals
Extracellular Matrix / drug effects
Fibrosis / diagnosis
Fibrosis / drug therapy*
Heart Diseases / diagnosis
Heart Diseases / drug therapy*
Humans

Substances

Adrenergic beta-Antagonists